Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD

May Validate Small Molecule Platform

The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.

Sanofi Lyon — Sanofi already has an anti-inflammation blockbuster in Dupixent, experience which could help bring C4X Discovery's candidate to market.

C4X Discovery (C4XD) is hoping its new partnership with Sanofi on an oral IL-17 inhibitor candidate could produce a rival to existing inflammatory blockbuster therapies.

The companies signed the deal worth up to €414m ($502m) for C4XD’s preclinical small molecule earlier this month, with an upfront payment of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

15 May 2025

• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.